ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
11 announcements
Krsnaa Diagnostics Ltd reported the successful passing of a special resolution via postal ballot approving the issuance of up to 16,21,000 convertible warrants to promoters.
Krsnaa Diagnostics executed a 15-year concession agreement with the Punjab Government to develop and operate PET-CT diagnostic facilities at four government hospitals.
Krsnaa Diagnostics received tax appellate orders for AY 2017-24 with aggregate disputed demands of ₹62.69 Crore. The company plans to file further appeals.
Krsnaa Diagnostics has filed its Business Responsibility and Sustainability Report for the financial year 2025-26 as required by regulatory listing obligations.
Krsnaa Diagnostics Limited has submitted the notice of its 16th Annual General Meeting, scheduled for September 28, 2026, along with the Annual Report for 2025-26.
Krsnaa reported 22% revenue growth but suffered margin compression due to heavy front-ended costs for the Rajasthan project. Management pivots to 'long-term value' to deflect from current EBITDA and PAT dips.
Krsnaa Diagnostics reported 22% revenue growth in Q1 FY27, driven by expanding retail business and PPP project scaling, despite margin pressure from Rajasthan operationalization.
Krsnaa Diagnostics Ltd reported revenue from operations of ₹235.5 Cr (+22.0% YoY) and net profit of ₹16.6 Cr (-19.0% YoY) for Q1 FY27.
Krsnaa Diagnostics reports 8% revenue growth and crossing ₹100cr PAT milestone in FY26, driven by PPP scaling and a sixfold growth in retail diagnostics.
Krsnaa Diagnostics reported FY26 revenue of ₹7,728 Mn (up 8% YoY) and PAT of ₹1,013 Mn (up 31% YoY). Strategy focuses on PPP model and aggressive retail expansion.
Krsnaa Diagnostics Ltd reported revenue from operations of ₹192.6 Cr (+3.5% YoY) and net profit of ₹41.7 Cr (+101.4% YoY) for Q4 FY26.